Advances in DLBCL
.jpg)
Worse Outcomes With Transformed Indolent Lymphomas Versus De Novo DLBCL
These investigators used SEER data to compare the outcomes of transformed indolent non-Hodgkin lymphomas with de novo DLBCL at a population level, a situation for which little data exist.
In DLBCL, a Molecular Signature Predicts Primary Treatment Resistance
These investigators assessed the potential benefit of a high-risk signature to evaluate the molecular drivers of primary treatment resistance in patients with DLBCL.
Medical Visits Drive Burden for Blood Cancer Caregivers
Modern treatments have shifted several blood cancers from acute to chronic conditions, but caregivers may pay a price. There are ways to help.